Abstract
Background: Depression is a mental disorder that affects a large part of the world's population. DHEA is a hormone that has long been attributed to the ability to improve depressive symptoms. However, few studies were conducted with depression individuals not resulting from other medical conditions.
Objective: To investigate whether DHEA is more effective than placebo in the treatment of depressive symptoms in subjects with depression not resulting from other psychiatric or medical comorbidities.
Methods: An electronic search was carried out using the keywords Dehydroepiandrosterone (Mesh) AND Depression (Mesh) in the following databases: Medical Literature databases Analysis and Retrieval System Online (Medline), Excerpta Medical Database (EMBASE), Latin American and Caribbean Health Sciences (LILACS) and the Cochrane Library through their website for relevant publications until June 2018. Only randomized clinical trials were included. The critical appraisal of the articles was performed using the Risk of Bias Tool from Cochrane Collaboration.
Results: The meta-analysis applied in this review pointed to a significant effect in favor of treatment with DHEA compared to placebo.
Conclusion: DHEA may be one more effective alternative between the drugs used in the treatment of depression.
Keywords: Dehydroepiandrosterone, DHEA treatment, depression, depression treatment, depressive disorder, depressive symptoms, mood disorders.
CNS & Neurological Disorders - Drug Targets
Title:Dehydroepiandrosterone (DHEA) for Depression: A Systematic Review and Meta-Analysis
Volume: 17 Issue: 9
Author(s): Clayton Peixoto*, Antonio Jose Grande, Mariana Bonotto Mallmann, Antonio Egídio Nardi, Adriana Cardoso and André Barciela Veras
Affiliation:
- Laboratory of Panic and Respiration, Institute of Psychiatry, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro,Brazil
Keywords: Dehydroepiandrosterone, DHEA treatment, depression, depression treatment, depressive disorder, depressive symptoms, mood disorders.
Abstract: Background: Depression is a mental disorder that affects a large part of the world's population. DHEA is a hormone that has long been attributed to the ability to improve depressive symptoms. However, few studies were conducted with depression individuals not resulting from other medical conditions.
Objective: To investigate whether DHEA is more effective than placebo in the treatment of depressive symptoms in subjects with depression not resulting from other psychiatric or medical comorbidities.
Methods: An electronic search was carried out using the keywords Dehydroepiandrosterone (Mesh) AND Depression (Mesh) in the following databases: Medical Literature databases Analysis and Retrieval System Online (Medline), Excerpta Medical Database (EMBASE), Latin American and Caribbean Health Sciences (LILACS) and the Cochrane Library through their website for relevant publications until June 2018. Only randomized clinical trials were included. The critical appraisal of the articles was performed using the Risk of Bias Tool from Cochrane Collaboration.
Results: The meta-analysis applied in this review pointed to a significant effect in favor of treatment with DHEA compared to placebo.
Conclusion: DHEA may be one more effective alternative between the drugs used in the treatment of depression.
Export Options
About this article
Cite this article as:
Peixoto Clayton *, Grande Jose Antonio , Mallmann Bonotto Mariana , Nardi Egídio Antonio, Cardoso Adriana and Veras Barciela André , Dehydroepiandrosterone (DHEA) for Depression: A Systematic Review and Meta-Analysis, CNS & Neurological Disorders - Drug Targets 2018; 17 (9) . https://dx.doi.org/10.2174/1871527317666180817153914
DOI https://dx.doi.org/10.2174/1871527317666180817153914 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Polymeric Nanoparticles of FMISO: Are Nano-Radiopharmaceuticals Better Than Conventional Ones?
Current Radiopharmaceuticals Effects of Palmitoylethanolamide and Luteolin in an Animal Model of Anxiety/Depression
CNS & Neurological Disorders - Drug Targets Towards More Efficient Glutathione Peroxidase Mimics: Substrate Recognition and Catalytic Group Assembly
Current Medicinal Chemistry Region-Specific Dendritic Spine Loss of Pyramidal Neurons in Dopamine Transporter Knockout Mice
Current Molecular Medicine C-Abl Tyrosine Kinase Signaling: A New Player in AD Tau Pathology
Current Alzheimer Research Targeting the Nogo Receptor Complex in Diseases of the Central Nervous System
Current Medicinal Chemistry Methylene Blue Inhibits the Function of α7-Nicotinic Acetylcholine Receptors
CNS & Neurological Disorders - Drug Targets The Association between TNF-alpha, IL-1 alpha and IL-10 with Alzheimer's Disease
Current Alzheimer Research Functional Annotation of Genes Overlapping Copy Number Variants in Autistic Patients: Focus on Axon Pathfinding
Current Genomics Synthesis of 8,10-disubstituted-triazoloperimidines from (E)-3-(dimethylamino)-1-(8- phenyl-8H-[1,2,4]triazolo[4,3-a]perimidin-10-yl)prop-2-en-1-one and Their Antimicrobial Activity
Current Organic Synthesis Alterations of Brain Membranes in Schizophrenia: Impact of Phospholipase A2
Current Topics in Medicinal Chemistry Antioxidants and Neuroprotection in the Adult and Developing Central Nervous System
Current Medicinal Chemistry Sleep and Sleep Disorders in Tourette Syndrome: What is Known and What is Still Unknown
Current Drug Therapy New Highlights in the Regulation of Cells Proliferation
Neuroscience and Biomedical Engineering (Discontinued) Formulation and Evaluation of Gastroretentive Microballoons Containing Baclofen for a Floating Oral Controlled Drug Delivery System
Current Drug Delivery Antitumor Potential and Possible Targets of Phenothiazine-Related Compounds
Current Drug Targets Phytocompounds as Potential Agents to Treat Obesity-Cardiovascular Ailments
Cardiovascular & Hematological Agents in Medicinal Chemistry Organelle Stress Sensors and Cell Death Mechanisms in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Highly Organized Nanostructures for Brain Drug Delivery - New Hope or Just a Fad?
CNS & Neurological Disorders - Drug Targets Recent Patents on Exoskeletal Rehabilitation Robot for Upper Limb
Recent Patents on Mechanical Engineering